Our research laboratory is affiliated with the Department of Genetics and Development and the Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center. We employ high-throughput genetic and (epi)genomic technologies to understand the mechanisms by which misregulation of chromatin modifications drive tumor development. Our goal is to apply insights from mechanistic studies to develop novel precision medicine and immunotherapy for cancer.
SEP 2019: Our first paper is published! A great collaborative effort that identifies H3K36 di-methylation as a key player in recruiting de novo DNA methyltransferase DNMT3A and maintaining intergenic DNA methylation. We hope that these findings will translate into better management of patients with cancers and overgrowth disorders that are associated with mutations in these enzymes.